One-in-ten patients with ischemic stroke have comorbid cancer. This number is expected to rise as cancer treatment improves, prolonging median survival. Furthermore, within the two-year span following an ischemic stroke event, an additional 3-5% of patients find themselves newly diagnosed with cancer. This Research Topic will explore the intersections between stroke and cancer. Notably, treatments for cancer, such as chemotherapy, radiotherapy, and surgical interventions, have all exhibited the potential to exacerbate the risk of stroke. Both cancer and stroke share common risk factors and numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. The influence of cancer on stroke pathophysiology may manifest directly or through the induction of coagulation disorders, ultimately precipitating a hypercoagulable state. In addition, cancer can exert an impact via infection-related mechanisms. The risk of stroke differs based on the type of cancer, its histological characteristics, and its stage. Cancers traditionally linked to venous thromboembolism, such as pancreatic, gastric, and lung cancers, appear to have the greatest likelihood of arterial thromboembolism. Cancer stage shows a direct correlation with the risk of stroke, and stage 4 cancers exhibit the highest risks, with an over tenfold increased risk during the initial month following a cancer diagnosis.
Cancer is increasingly gaining recognition as a contributing factor to ischemic strokes. Recent studies have shed light on cancer-related strokes as an emerging subtype, characterized by distinct pathophysiological mechanisms. The goal of this Research Topic is to acquire a comprehensive understanding of the prevalence, prognosis, and predictors of stroke in individuals with cancer. Additionally, it seeks to explore the clinical implications, epidemiological trends, and predictive factors underlying this critical association Detecting occult cancer in stroke patients may involve the consideration of potential biomarkers, including elevated levels of D-dimer, fibrinogen, and C-reactive protein, the occurrence of infarction in multiple vascular territories, and indicators of compromised nutritional status. It is important to mention that individuals suffering from cancer-related strokes may not receive stroke care following recommended guidelines. Considering the substantial health risks and fatalities associated with both conditions, it is crucial to acquire a thorough comprehension of the connection between stroke and cancer.
Our Research Topic, "When Two Powers Converge" seeks to explore the prevalence, prognosis, and predictors of stroke in individuals with cancer. It brings together cutting-edge research at the nexus of oncology and neurology, aiming to shed light on the epidemiological trends, clinical implications, and predictive factors that underlie this crucial association. We welcome the submission of any type of manuscript supported by the journal (original research, brief research reports, case reports, etc.) that focus on, but are not limited to, the following themes:
- Prevalence, incidence and mortality of stroke among cancer patients
- Prevalence of stroke in patients under chemotherapy or radiotherapy
- Shared and overlapping risk factors for ischemic stroke and cancer
- Mechanisms responsible for cancer patients increased risk of stroke
- Clinical predictors of stroke in cancer patients
- Therapeutic strategies for both primary and secondary stroke prevention in patients with cancer: pharmacological and non-pharmacological therapies
- prognosis and clinical predictors of stroke related cancer
Keywords:
cancer stroke Oncology-Stroke Tumor-Stroke Coagulopathy-Cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
One-in-ten patients with ischemic stroke have comorbid cancer. This number is expected to rise as cancer treatment improves, prolonging median survival. Furthermore, within the two-year span following an ischemic stroke event, an additional 3-5% of patients find themselves newly diagnosed with cancer. This Research Topic will explore the intersections between stroke and cancer. Notably, treatments for cancer, such as chemotherapy, radiotherapy, and surgical interventions, have all exhibited the potential to exacerbate the risk of stroke. Both cancer and stroke share common risk factors and numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. The influence of cancer on stroke pathophysiology may manifest directly or through the induction of coagulation disorders, ultimately precipitating a hypercoagulable state. In addition, cancer can exert an impact via infection-related mechanisms. The risk of stroke differs based on the type of cancer, its histological characteristics, and its stage. Cancers traditionally linked to venous thromboembolism, such as pancreatic, gastric, and lung cancers, appear to have the greatest likelihood of arterial thromboembolism. Cancer stage shows a direct correlation with the risk of stroke, and stage 4 cancers exhibit the highest risks, with an over tenfold increased risk during the initial month following a cancer diagnosis.
Cancer is increasingly gaining recognition as a contributing factor to ischemic strokes. Recent studies have shed light on cancer-related strokes as an emerging subtype, characterized by distinct pathophysiological mechanisms. The goal of this Research Topic is to acquire a comprehensive understanding of the prevalence, prognosis, and predictors of stroke in individuals with cancer. Additionally, it seeks to explore the clinical implications, epidemiological trends, and predictive factors underlying this critical association Detecting occult cancer in stroke patients may involve the consideration of potential biomarkers, including elevated levels of D-dimer, fibrinogen, and C-reactive protein, the occurrence of infarction in multiple vascular territories, and indicators of compromised nutritional status. It is important to mention that individuals suffering from cancer-related strokes may not receive stroke care following recommended guidelines. Considering the substantial health risks and fatalities associated with both conditions, it is crucial to acquire a thorough comprehension of the connection between stroke and cancer.
Our Research Topic, "When Two Powers Converge" seeks to explore the prevalence, prognosis, and predictors of stroke in individuals with cancer. It brings together cutting-edge research at the nexus of oncology and neurology, aiming to shed light on the epidemiological trends, clinical implications, and predictive factors that underlie this crucial association. We welcome the submission of any type of manuscript supported by the journal (original research, brief research reports, case reports, etc.) that focus on, but are not limited to, the following themes:
- Prevalence, incidence and mortality of stroke among cancer patients
- Prevalence of stroke in patients under chemotherapy or radiotherapy
- Shared and overlapping risk factors for ischemic stroke and cancer
- Mechanisms responsible for cancer patients increased risk of stroke
- Clinical predictors of stroke in cancer patients
- Therapeutic strategies for both primary and secondary stroke prevention in patients with cancer: pharmacological and non-pharmacological therapies
- prognosis and clinical predictors of stroke related cancer
Keywords:
cancer stroke Oncology-Stroke Tumor-Stroke Coagulopathy-Cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.